Associations - AR positive

AR positive AR positive	Salivary Gland Cancer Salivary Gland Cancer	AR positive AR positive	Salivary Gland Cancer Salivary Gland Cancer	leuprolide acetate Sensitive: A2 - Guideline	leuprolide acetate Sensitive: A2 - Guideline
AR positive AR positive	Salivary Gland Cancer Salivary Gland Cancer	AR positive AR positive	Salivary Gland Cancer Salivary Gland Cancer	bicalutamide Sensitive: A2 - Guideline	bicalutamide Sensitive: A2 - Guideline
AR positive AR positive	Triple Negative Breast Cancer Triple Negative Breast Cancer	AR positive AR positive	Triple Negative Breast Cancer Triple Negative Breast Cancer	enzalutamide Sensitive: C2 – Inclusion Criteria	enzalutamide Sensitive: C2 – Inclusion Criteria
AR positive AR positive	Breast Cancer Breast Cancer	AR positive AR positive	Breast Cancer Breast Cancer	GT0918 Sensitive: C2 – Inclusion Criteria	GT0918 Sensitive: C2 – Inclusion Criteria
AR positive AR positive	Salivary Gland Cancer Salivary Gland Cancer	AR positive AR positive	Salivary Gland Cancer Salivary Gland Cancer	leuprolide acetate + bicalutamide Sensitive: C3 – Early Trials	leuprolide acetate + bicalutamide Sensitive: C3 – Early Trials
AR positive AR positive	Triple Negative Breast Cancer Triple Negative Breast Cancer	AR positive AR positive	Triple Negative Breast Cancer Triple Negative Breast Cancer	palbociclib Sensitive: C3 – Early Trials	palbociclib Sensitive: C3 – Early Trials
AR positive AR positive	Triple Negative Breast Cancer Triple Negative Breast Cancer	AR positive AR positive	Triple Negative Breast Cancer Triple Negative Breast Cancer	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
AR positive AR positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	AR positive AR positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	enobosarm Sensitive: C3 – Early Trials	enobosarm Sensitive: C3 – Early Trials
AR positive AR positive	Salivary Gland Cancer Salivary Gland Cancer	AR positive AR positive	Salivary Gland Cancer Salivary Gland Cancer	abiraterone acetate Sensitive: C3 – Early Trials	abiraterone acetate Sensitive: C3 – Early Trials
AR positive AR positive	Ovarian Cancer Ovarian Cancer	AR positive AR positive	Ovarian Cancer Ovarian Cancer	enzalutamide Sensitive: C3 – Early Trials	enzalutamide Sensitive: C3 – Early Trials
AR positive AR positive	Prostate Cancer Prostate Cancer	AR positive AR positive	Prostate Cancer Prostate Cancer	XY123 Sensitive: C4 – Case Studies	XY123 Sensitive: C4 – Case Studies
AR positive AR positive	Urothelial Cancer Urothelial Cancer	AR positive AR positive	Urothelial Cancer Urothelial Cancer	silodosin Resistant: D – Preclinical	silodosin Resistant: D – Preclinical
AR positive AR positive	Breast Cancer Breast Cancer	AR positive AR positive	Breast Cancer Breast Cancer	FT-6876 Sensitive: D – Preclinical	FT-6876 Sensitive: D – Preclinical
AR positive AR positive	Triple Negative Breast Cancer Triple Negative Breast Cancer	AR positive AR positive	Triple Negative Breast Cancer Triple Negative Breast Cancer	apalutamide Sensitive: D – Preclinical	apalutamide Sensitive: D – Preclinical
AR positive AR positive	Prostate Cancer Prostate Cancer	AR positive AR positive	Prostate Cancer Prostate Cancer	abemaciclib Sensitive: D – Preclinical	abemaciclib Sensitive: D – Preclinical
AR positive AR positive	Prostate Cancer Prostate Cancer	AR positive AR positive	Prostate Cancer Prostate Cancer	GT0918 Sensitive: D – Preclinical	GT0918 Sensitive: D – Preclinical
AR positive AR positive	Triple Negative Breast Cancer Triple Negative Breast Cancer	AR positive AR positive	Triple Negative Breast Cancer Triple Negative Breast Cancer	darolutamide Sensitive: D – Preclinical	darolutamide Sensitive: D – Preclinical